Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases
- PMID: 25914229
- PMCID: PMC7105169
- DOI: 10.1002/pds.3778
Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases
Abstract
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) carry a high mortality risk. While identifying clinical and genetic risk factors for these conditions has been hindered by their rarity, large electronic health databases hold promise for identifying large numbers of cases for study, especially with the introduction in 2008 of ICD-9 codes more specific for these conditions.
Objective: The objective of this study is to estimate the validity of ICD-9 codes for ascertaining SJS/TEN in 12 collaborating research units in the USA, covering almost 60 million lives.
Methods: From the electronic databases at each site, we ascertained potential cases of SJS/TEN using ICD-9 codes. At five sites, a subset of medical records was abstracted and standardized criteria applied by board-certified dermatologists to adjudicate diagnoses. Multivariate logistic regression was used to identify factors independently associated with validated SJS/TEN cases.
Results: A total of 56 591 potential cases of SJS/TEN were identified. A subset of 276 charts was selected for adjudication and 39 (of the 276) were confirmed as SJS/TEN. Patients with the ICD-9 codes introduced after 2008 were more likely to be confirmed as cases (OR 3.32; 95%CI 0.82, 13.47) than those identified in earlier years. Likelihood of case status increased with length of hospitalization. Applying the probability of case status to the 56 591 potential cases, we estimated 475-875 to be valid SJS/TEN cases.
Conclusion: Newer ICD-9 codes, along with length of hospitalization, identified patients with a high likelihood of SJS/TEN. This is important for identification of subjects for future pharmacogenomics studies.
Keywords: Stevens-Johnson syndrome; pharmacoepidemiology; toxic epidermal necrolysis.
Copyright © 2015 John Wiley & Sons, Ltd.
Conflict of interest statement
CONFLICT OF INTEREST
The authors declare no conflict of interest.
References
-
- Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug-induced skin, nail and hair disorders. Drug Saf 2007; 30(11): 1011–1030. - PubMed
-
- Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600–1608. - PubMed
-
- Hung SI, Chung WH, Chen YT. HLA-B genotyping to detect carbamazepine-induced Stevens–Johnson syndrome: implications for personalizing medicine. Pers Med 2005; 2(3): 225–237. - PubMed
-
- Man CBL, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48: 1015–1018. - PubMed
-
- Lim KS, Kwan P, Tan CT. Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review. Neurol Asia 2008; 13: 15–21.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
